HF 22: HELIOS-A: Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis

Published: 24 May 2022

  • Views:

    Views Icon 94
  • Likes:

    Heart Icon 0

In this short interview, Dr Pablo Garcia-Pavia (Hospital Universitario Puerta de Hierro Majadahonda, ES) shares the findings from the phase 3 study, HELIOS-A (NCT03759379).

The study, presented at Heart Failure 2022, investigated the efficacy and safety of vutrisiran (ALN-TTRSC02) in patients with hereditary transthyretin amyloidosis (hATTR amyloidosis).

Discussion Points
1. Study Background
2. Vutrisiran 
3. Study Design, Eligibility Criteria & Outcome Measures
4. Key Findings
5. Take-Home Messages
6. Next Steps

Recorded at Heart Failure 2022, Madrid.

Videographers: Oliver Miles, Tom Green and Mike Knight
Interviewer: Mirjam Boros